Literature DB >> 21833801

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient.

J Paul Duic, Jai Grewal, Kerry McConie, Harry Staszewski, Jonathan Haas, Santosh Kesari.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21833801     DOI： 10.1007/s11060-011-0675-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  3 in total

1.  A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.

Authors:  A Kellum; A Jagiello-Gruszfeld; I N Bondarenko; R Patwardhan; C Messam; Y Mostafa Kamel
Journal:  Curr Med Res Opin       Date:  2010-10       Impact factor: 2.580

Review 2.  Eltrombopag: a novel oral thrombopoietin receptor agonist.

Authors:  Shelby L Corman; Rima A Mohammad
Journal:  Ann Pharmacother       Date:  2010-05-11       Impact factor: 3.154

3.  Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

Authors:  Julian M Jenkins; Daphne Williams; Yanli Deng; Joanne Uhl; Valerie Kitchen; David Collins; Connie L Erickson-Miller
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.